A Three-Arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL) of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell Non-Hodgkin s Lymphoma (NHL) and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Other Specified Types Of Non-hodgkin Lymphoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    Diagnosis of relapsed/refractory CLL or histologically confirmed relapsed/refractory SLL or FL, marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS) (germinal center B-cell type or activated B-cell type), and high-grade B-cell lymphoma (NOS or with myelocytomatosis (MYC) and BCL2 and/or BCL6 rearrangements).

You may not be eligible for this study if the following are true:

  • 1) Known active histological transformation from CLL to an aggressive lymphoma (i.e.Richter’s transformation). Note that biopsy documentation of the absence or presence of transformation is not required. 2) Major surgical procedure within 4 weeks of beginning study drugs, or anticipation of need for a major surgical procedure within 4 weeks of Day 0. 3) Uncontrolled autoimmune hemolytic anemia or immune thrombocytopeni.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.